Biomedicines (May 2022)

A Very Rare Variant in <i>SREBF2</i>, a Possible Cause of Hypercholesterolemia and Increased Glycemic Levels

  • Ana-Bárbara García-García,
  • Sergio Martínez-Hervás,
  • Santiago Vernia,
  • Carmen Ivorra,
  • Inés Pulido,
  • Juan-Carlos Martín-Escudero,
  • Marta Casado,
  • Julián Carretero,
  • José T. Real,
  • Felipe Javier Chaves

DOI
https://doi.org/10.3390/biomedicines10051178
Journal volume & issue
Vol. 10, no. 5
p. 1178

Abstract

Read online

Patients with high cholesterol and glucose levels are at high risk for cardiovascular disease. The Sterol Regulatory Element Binding Protein (SREBP) system regulates genes involved in lipid, cholesterol and glucose pathways. Autosomal Dominant Hypercholesterolemias (ADHs) are a group of diseases with increased cholesterol levels. They affect 1 out of every 500 individuals. About 20–30% of patients do not present any mutation in the known genes (LDLR, APOB and PCSK9). ADHs constitute a good model to identify the genes involved in the alteration of lipid levels or possible therapeutic targets. In this paper, we studied whether a mutation in the SREBP system could be responsible for ADH and other metabolic alterations present in these patients. Forty-one ADH patients without mutations in the main responsible genes were screened by direct sequencing of SREBP system genes. A luciferase reporter assay of the found mutation and an oral glucose tolerance test in carriers and non-carriers were performed. We found a novel mutation in the SREBF2 gene that increases transcription levels and cosegregates with hypercholesterolemia, and we found increased glucose levels in one family. SREBP2 is known to be involved in cholesterol synthesis, plasma levels and glucose metabolism in humans. The found mutation may involve the SREBF2 gene in hypercholesterolemia combined with hyperglycemia.

Keywords